Effect of polymeric excipients on nucleation and crystal growth kinetics of amorphous fluconazole
Source abstract
Abstract
Amorphous solids have been widely used to improve the solubility and oral bioavailability of poorly water-soluble drugs. Biocompatible polymeric materials are usually incorporated into formulations to inhibit the crystallization of high-energy amorphous drugs. Crystallization typically consists of two steps, nucleation and crystal growth. The impacts of polymeric excipients on the crystal growth of amorphous drugs have been intensively studied. However, the nucleation behaviors of amorphous drugs in the presence of polymers remain largely unexplored. Herein, we report that three chemically distinct polymers show significantly different effects on nucleation kinetics of amorphous fluconazole (FCZ), a classical antifungal drug. The addition of 10% w/w HPMCAS shows the largest inhibitory effect on the nucleation rates of FCZ, while the same amount of PVP has only a minor effect. Conversely, the nucleation rates for both polymorphs of FCZ are significantly increased in the presence of PEO. In addition, the polymeric additives are found to influence the kinetics of nucleation and crystal growth to a similar extent, suggesting that the two processes may share a similar kinetic barrier. The present study is helpful in the optimization of formulations of amorphous solid dispersions and understanding the nucleation behavior of polymorphic drugs.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Microencapsulation and Drying Processes · Drug Solubulity and Delivery Systems · Crystallization and Solubility Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Natural Medicines
Department of Pharmaceutics
School of Pharmacy
China Pharmaceutical University
Nanjing 210009
Funding
National Natural Science Foundation of China · State Key Laboratory of Natural Medicines · Natural Science Foundation of Jiangsu Province · China Postdoctoral Science Foundation · Outstanding Youth Fund of Jiangsu Province of China
References (40)
Show source-provided references
1. Yu · Adv. Drug Delivery Rev. · 2001 · 48 · 2710.1016/S0169-409X(01)00098-9 ↗
2. Jermain · Int. J. Pharm. · 2018 · 535 · 37910.1016/j.ijpharm.2017.10.051 ↗
3. Duong · Opin. Drug Deliv. · 2016 · 13 · 168110.1080/17425247.2016.1198769 ↗
4. Palpandi · Int. J. Pharm. · 2020 · 586 · 11956010.1016/j.ijpharm.2020.119560 ↗
5. Mistry · Cryst. Growth Des. · 2016 · 16 · 514110.1021/acs.cgd.6b00714 ↗
6. Kothari · Mol. Pharmaceutics · 2015 · 12 · 16210.1021/mp5005146 ↗
7. A. Newman , Pharmaceutical.Amorphous Solid Dispersions , John Wiley & Sons , NJ , 2015 , pp. 179–217
8. Nair · AAPS PharmSciTech · 2020 · 21 · 30910.1208/s12249-020-01849-z ↗
9. Shi · Mol. Pharmaceutics · 2017 · 14 · 226210.1021/acs.molpharmaceut.7b00097 ↗
10. Shi · Mol. Pharmaceutics · 2017 · 14 · 469410.1021/acs.molpharmaceut.7b00854 ↗
11. Powell · J. Phys. Chem. B · 2013 · 117 · 1033410.1021/jp406418n ↗
12. Zhang · Mol. Pharmaceutics · 2020 · 17 · 206410.1021/acs.molpharmaceut.0c00220 ↗
13. Huang · J. Phys. Chem. B · 2017 · 121 · 196310.1021/acs.jpcb.6b11816 ↗
14. Alonzo · Cryst. Growth Des. · 2012 · 12 · 153810.1021/cg201590j ↗
15. Huang · J. Chem. Phys. · 2018 · 149 · 05450310.1063/1.5042112 ↗
16. Trasi · CrystEngComm · 2012 · 14 · 518810.1039/c2ce25374g ↗
17. Miyazaki · Int. J. Pharm. · 2011 · 407 · 11110.1016/j.ijpharm.2011.01.035 ↗
18. Konno · J. Pharm. Sci. · 2006 · 95 · 269210.1002/jps.20697 ↗
19. Yao · Cryst. Growth Des. · 2020 · 20 · 23710.1021/acs.cgd.9b01095 ↗
20. Kastelic · Cryst. Growth Des. · 2010 · 10 · 494310.1021/cg1010117 ↗
21. Surov · Cryst. Growth Des. · 2019 · 20 · 121810.1021/acs.cgd.9b01490 ↗
22. Andronis · J. Non-Cryst. Solids · 2000 · 271 · 23610.1016/S0022-3093(00)00107-1 ↗
23. Shi · Cryst. Growth Des. · 2016 · 16 · 327910.1021/acs.cgd.6b00252 ↗
24. Sun · AAPS J. · 2012 · 14 · 38010.1208/s12248-012-9345-6 ↗
25. Niraj · Cryst. Growth Des. · 2012 · 12 · 322110.1021/cg300370q ↗
26. Zhang · Mol. Pharmaceutics · 2019 · 16 · 138510.1021/acs.molpharmaceut.8b01331 ↗
27. Bai · Nature · 2019 · 576 · 43710.1038/s41586-019-1827-6 ↗
28. Fokin · J. Non-Cryst. Solids · 2006 · 352 · 268110.1016/j.jnoncrysol.2006.02.074 ↗
29. Karthika · Cryst. Growth Des. · 2016 · 16 · 666310.1021/acs.cgd.6b00794 ↗
30. Tipeev · J. Phys. Chem. B · 2020 · 124 · 797910.1021/acs.jpcb.0c05480 ↗
31. Gutzow · J. Cryst. Growth · 1977 · 42 · 1510.1016/0022-0248(77)90172-5 ↗
32. Mino · J. Pharm. Sci. · 2004 · 93 · 60110.1002/jps.10541 ↗
33. Karanam · Cryst. Growth Des. · 2011 · 12 · 24010.1021/cg201005y ↗
34. Sarode · Mol. Pharmaceutics · 2013 · 10 · 366510.1021/mp400165b ↗
35. Bhardwaj · Mol. Pharmaceutics · 2014 · 11 · 422810.1021/mp5004515 ↗
36. Lu · Mol. Pharmaceutics · 2020 · 17 · 258510.1021/acs.molpharmaceut.0c00268 ↗
37. Konno · Pharm. Res. · 2008 · 25 · 96910.1007/s11095-007-9331-3 ↗
38. Kestur · Cryst. Growth Des. · 2013 · 13 · 434910.1021/cg400708p ↗
39. Tian · Cryst. Growth Des. · 2017 · 17 · 646710.1021/acs.cgd.7b01145 ↗
40. Madejczyk · Mol. Pharmaceutics · 2017 · 14 · 211610.1021/acs.molpharmaceut.7b00228 ↗